V. Pechtner

1.6k total citations
15 papers, 1.3k citations indexed

About

V. Pechtner is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, V. Pechtner has authored 15 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Molecular Biology and 3 papers in Surgery. Recurrent topics in V. Pechtner's work include Diabetes Treatment and Management (12 papers), Metabolism, Diabetes, and Cancer (9 papers) and Diabetes Management and Research (6 papers). V. Pechtner is often cited by papers focused on Diabetes Treatment and Management (12 papers), Metabolism, Diabetes, and Cancer (9 papers) and Diabetes Management and Research (6 papers). V. Pechtner collaborates with scholars based in United States, Italy and United Kingdom. V. Pechtner's co-authors include R. Gentilella, Linda Shurzinske, Guillermo E. Umpierrez, Federico Pérez Manghi, Santiago Tofé, Francesco Giorgino, Agostino Consoli, Jui‐Hung Sun, Alan G. Zimmermann and Marian Benroubi and has published in prestigious journals such as American Journal of Clinical Nutrition, Diabetes Care and Diabetic Medicine.

In The Last Decade

V. Pechtner

15 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
V. Pechtner United States 11 916 486 254 241 222 15 1.3k
Katsuya Yamazaki Japan 18 471 0.5× 248 0.5× 197 0.8× 206 0.9× 162 0.7× 49 1.2k
L. Monnier France 24 918 1.0× 305 0.6× 305 1.2× 304 1.3× 375 1.7× 70 1.7k
Matthews Dr United Kingdom 8 767 0.8× 311 0.6× 255 1.0× 141 0.6× 77 0.3× 14 993
L. Patti Italy 26 807 0.9× 246 0.5× 294 1.2× 471 2.0× 267 1.2× 53 1.5k
Y. Miyazaki United States 15 833 0.9× 695 1.4× 333 1.3× 386 1.6× 44 0.2× 17 1.5k
Henna Cederberg Finland 21 536 0.6× 551 1.1× 360 1.4× 451 1.9× 133 0.6× 37 1.5k
Kazutaka Aoki Japan 19 677 0.7× 300 0.6× 295 1.2× 154 0.6× 34 0.2× 48 1.0k
Annette M. Chang United States 16 811 0.9× 388 0.8× 460 1.8× 300 1.2× 56 0.3× 30 1.4k
Ming-Sheng Zhou United States 19 406 0.4× 237 0.5× 153 0.6× 359 1.5× 209 0.9× 22 1.2k
Dominik Dahl Germany 15 679 0.7× 382 0.8× 257 1.0× 636 2.6× 28 0.1× 26 1.4k

Countries citing papers authored by V. Pechtner

Since Specialization
Citations

This map shows the geographic impact of V. Pechtner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Pechtner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Pechtner more than expected).

Fields of papers citing papers by V. Pechtner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Pechtner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Pechtner. The network helps show where V. Pechtner may publish in the future.

Co-authorship network of co-authors of V. Pechtner

This figure shows the co-authorship network connecting the top 25 collaborators of V. Pechtner. A scholar is included among the top collaborators of V. Pechtner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Pechtner. V. Pechtner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Gentilella, R., et al.. (2018). Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?. Diabetes/Metabolism Research and Reviews. 35(1). e3070–e3070. 181 indexed citations
2.
Giorgino, Francesco, et al.. (2018). Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement. Patient Preference and Adherence. Volume 12. 707–719. 54 indexed citations
3.
Reach, G., et al.. (2017). Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes & Metabolism. 43(6). 501–511. 183 indexed citations
4.
Pechtner, V., et al.. (2017). A New Approach to Drug Therapy: Fc-Fusion Technology. 7(1). 16 indexed citations
5.
6.
Giorgino, Francesco, Marian Benroubi, Jui‐Hung Sun, Alan G. Zimmermann, & V. Pechtner. (2015). Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes Care. 38(12). 2241–2249. 205 indexed citations
7.
Grunberger, George, Thomas Först, Laura Fernández Landó, et al.. (2015). Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide. Diabetic Medicine. 33(3). 391–394. 10 indexed citations
8.
9.
Reaney, Matthew, Miao Yu, Mark Lakshmanan, V. Pechtner, & Kate Van Brunt. (2015). Treatment satisfaction in people with type 2 diabetes mellitus treated with once‐weekly dulaglutide: data from the AWARD ‐1 and AWARD ‐3 clinical trials. Diabetes Obesity and Metabolism. 17(9). 896–903. 26 indexed citations
10.
11.
Umpierrez, Guillermo E., Santiago Tofé, Federico Pérez Manghi, Linda Shurzinske, & V. Pechtner. (2014). Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3). Diabetes Care. 37(8). 2168–2176. 274 indexed citations
12.
Giorgino, Francesco, Marian Benroubi, Jui‐Hung Sun, Alan G. Zimmermann, & V. Pechtner. (2014). Efficacy and Safety of Once Weekly Dulaglutide vs. Insulin Glargine in Combination with Metformin and Glimepiride in Type 2 Diabetes Patients (AWARD-2). Canadian Journal of Diabetes. 38(5). S4–S4. 13 indexed citations
13.
Umpierrez, Guillermo E., Federico Pérez Manghi, Santiago Tofé, Linda Shurzinske, & V. Pechtner. (2013). 1.5 Efficacy and Safety of Dulaglutide vs. Metformin in Type 2 Diabetes (AWARD-3) (69-OR). 11(3). 78–78. 2 indexed citations
14.
Kabir, Morvarid, Geraldine Skurnik, Nadia Naour, et al.. (2007). Treatment for 2 mo with n−3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. American Journal of Clinical Nutrition. 86(6). 1670–1679. 236 indexed citations
15.
Kabir, Morvarid, Geraldine Skurnik, Nadia Naour, et al.. (2007). Treatment for 2 mo with n−3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. American Journal of Clinical Nutrition. 86(6). 1670–1679. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katsuya Yamazaki Breakdown of academic impact, for papers by L. Monnier Breakdown of academic impact, for papers by Matthews Dr Breakdown of academic impact, for papers by L. Patti Breakdown of academic impact, for papers by Y. Miyazaki Breakdown of academic impact, for papers by Henna Cederberg Breakdown of academic impact, for papers by Kazutaka Aoki Breakdown of academic impact, for papers by Annette M. Chang Breakdown of academic impact, for papers by Ming-Sheng Zhou Breakdown of academic impact, for papers by Dominik Dahl
Rankless by CCL
2026